Ritter Pharmaceuticals Inc (RTTR) was Reiterated by Maxim Group to “Buy” while Lowering the Price Target of the company shares to $ 6 from a previous price target of $7 . Maxim Group advised their investors in a research report released on Aug 15, 2016.
Ritter Pharmaceuticals Inc closed down -0.0076 points or -0.59% at $1.28 with 20,525 shares getting traded on Friday. Post opening the session at $1.27, the shares hit an intraday low of $1.25 and an intraday high of $1.43 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jan 11, 2016, Matthew W Foehr (director) purchased 13,000 shares at $1.64 per share price. According to the SEC, on Jan 8, 2016, Michael D Step (CEO) purchased 27,000 shares at $1.48 per share price. On Jun 26, 2015, Noah Doyle (director) purchased 800,000 shares at $5.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Ritter Pharmaceuticals Inc. develops therapeutic products which modulate the human gut microbiome to treat gastrointestinal diseases. The Company is engaged in human gut health research by exploring the metabolic capacity of the gut microbiota. The Company’s platform is based on selectively colonizing microbiota (increasing beneficial bacteria) in the colon and thus changing the colon’s composition of microbiota. The Company’s first microbiome modulator RP-G28 is an orally administered galacto-oligosaccharide for the reduction of symptoms associated with lactose intolerance. RP-G28 is used for the growth of lactose-metabolizing bacteria in the colon such as bifid bacteria and lactobacilli. Its RP-G28 reduces the symptoms and frequency of episodes of abdominal pain which is associated with lactose intolerance. The primary endpoints included tracking patients’ gastrointestinal symptoms through a patient-reported symptom assessment instrument.